Introduction/Background Endometrial cancers have been traditionally divided into two subtypes based on histological characteristics, expression of hormone receptors and grade; genomic/immunohistochemistry based molecular classification has been recommended recently. This prospective study aims to investigate the possible relationship between molecular profile and clinicopathological features in patients diagnosed with endometrial cancer.

Methodology PMS-2, MSH-6, MLH-1, MSH-2 and p53 were evaluated immunohistochemically from selected formalin-fixed paraffin-embedded blocks that were obtained from 60 patients with endometrial cancer. Sequence analyzes of POLE gene 9. and 13. exons were performed from genomic DNA.

Results Patients were divided into 4 groups according to molecular classification. One patient (%1,7) had POLE mutation, 15 patients (%25) had MMRd, 41 patients (%68,3) belonged to NSMP group, and 3 patients (%5) had p53 mutation. Histology, stage, grade, myometrial invasion, lymphovascular space invasion, cervical involvement, peritoneal cytology, survival, and recurrence were compared with respect to molecular classification and only a statistically significant difference was found in terms of histology (p<0,05). A significant positive correlation was found between body mass index and CA125 levels (p<0,05). Moreover, there was a significant positive correlation between tumor size and both stage and grade.

Conclusion Large scale and long-term studies are required to clarify the relationship among molecular classification and clinicopathological features in endometrial cancer.

Disclosures The mean follow-up period of the patients was 16,32 months. Overall survival was 26,70 months (range: 26,11–27,29 months) and disease-free survival was 25,97 months (range: 24,83–27,11 months). One patient with both MMRd and p53 mutation died during the follow-up period. POLE mutation was detected in one patient and this case is under follow-up without recurrence.